Search results for "Proton pump"

showing 10 items of 50 documents

Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors.

2007

Antisecretory drugs are effective antiulcer agents, but its chronic use generates hypergastrinemia and accelerates the development of atrophic gastritis in Helicobacter pylori-positive patients. We have recently shown that gastrin exerts a proinflammatory effect in rats through CCK-2 receptor activation that contributes to the inflammation induced by H. pylori. The present study was designed to examine whether gastrin hypersecretion in response to treatment with antisecretory drugs induces an inflammatory response that could promote mucosal atrophy. The effects of omeprazole or famotidine on leukocyte/endothelial cell interactions in vivo were analyzed in rat mesenteric venules using intrav…

Malemedicine.medical_specialtyProglumidemedicine.drug_classInflammationCD18Cell CommunicationProinflammatory cytokineRats Sprague-DawleyInternal medicineGastrinsmedicineLeukocytesAnimalsOmeprazoleGastrinPharmacologyInflammationMicroscopy Videobusiness.industryEndothelial CellsProton Pump InhibitorsReceptor antagonistAnti-Ulcer AgentsFlow CytometryImmunohistochemistryReceptor Cholecystokinin BRatsFamotidineChemotaxis LeukocyteEndocrinologyGastric MucosaMolecular Medicinemedicine.symptombusinessmedicine.drugThe Journal of pharmacology and experimental therapeutics
researchProduct

Evaluation of main functional dyspepsia symptoms after probiotic administration in patients receiving conventional pharmacological therapies

2021

Objective Postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) are the two main forms of functional dyspepsia (FD). Probiotics are a promising therapy for FD, but current data remains heterogeneous. This work aims to evaluate a probiotic combination of Lacticaseibacillus rhamnosus LR04 (DSM 16605), Lactiplantibacillus pentosus LPS01 (DSM 21980), Lactiplantibacillus plantarum LP01 (LMG P-21021), and Lactobacillus delbrueckii subsp. delbruekii LDD01 (DMS 22106), alone or together with other pharmacological therapies, for clinical improvement of symptoms associated with FD. Methods Patients with FD were enrolled and divided into two groups: PDS and EPS. Probiotic alone or co…

Medicine (General)medicine.medical_specialtyBiochemistryEpigastric painlaw.invention03 medical and health sciencesProbioticR5-9200302 clinical medicinelawInternal medicineHumansMedicineIn patientDyspepsiabusiness.industryProbioticsBiochemistry (medical)Clinical Research Reportfood and beveragesProton Pump InhibitorsSyndromeCell BiologyGeneral MedicineAbdominal PainDistress030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFunctional disordersbusinessJournal of International Medical Research
researchProduct

Kinetics of proton release and uptake by channelrhodopsin-2

2012

Electrophysiological experiments showed that the light-activated cation channel channelrhodopsin-2 (ChR2) pumps protons in the absence of a membrane potential. We determined here the kinetics of transient pH change using a water-soluble pH-indicator. It is shown that ChR2 released protons prior to uptake with a stoichiometry of 0.3 protons per ChR2. Comparison to the photocycle kinetics revealed that proton release and uptake match rise and decay of the View the MathML sourceP3520 intermediate. As the View the MathML sourceP3520 state also represents the conductive state of cation channeling, the concurrence of proton pumping and channel gating implies an intimate mechanistic link of the tw…

Models MolecularRhodopsinProtonKineticsBiophysicsAnalytical chemistryChannelrhodopsinBacteriorhodopsinBiochemistry530Protein Structure SecondaryProton transferStructural BiologyGeneticsMolecular BiologyIon channelMembrane potentialbiologyChemistryfungiBacteriorhodopsinBiological TransportCell BiologyHydrogen-Ion ConcentrationProton PumpsOptogeneticsKineticsRhodopsinBiophysicsbiology.proteinProtonsIon channelStoichiometry
researchProduct

The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

2018

Purpose: Analyze the role of somatostatin analogues (SSAs) in the treatment of sporadic and MEN1-related gastrinomas, trying to define whether recent trials have changed the landscape of gastrinoma therapy. Methods: We evaluate the rationale of SSA use in the treatment of gastrinomas, summarize the current literature concerning the effect of SSAs on the control of Zollinger-Ellison syndrome (ZES) and gastrinomas tumor progression and discuss their role in the most recent guidelines. Results: The medical treatment of gastrinoma and related ZES is aimed at controlling acid hypersecretion and tumor progression, in inoperable patients. The use of proton pump inhibitors (PPIs) to control the syn…

Oncologymedicine.medical_specialtyProton Pump InhibitorAntineoplastic Agents HormonalEndocrinology Diabetes and MetabolismGastrinoma; neuroendocrine tumours; somatostatin; somatostatin analogues; endocrinology; diabetes and metabolism; endocrinologyNeuroendocrine tumorssomatostatinOctreotideSomatostatin analogueSettore MED/13 - EndocrinologiaZollinger-Ellison Syndrome03 medical and health sciencesendocrinology0302 clinical medicineInternal medicineNeuroendocrine tumourmedicineHumansProgression-free survivaldiabetes and metabolismGastrinomaMedical treatmentsomatostatin analoguesbusiness.industryDisease progressionPancreatic NeoplasmProton Pump Inhibitorsmedicine.diseasedigestive system diseasesZollinger-Ellison syndromePancreatic NeoplasmsEndocrinologySomatostatinTreatment OutcomeTumor progression030220 oncology & carcinogenesisGastrinoma030211 gastroenterology & hepatologyneuroendocrine tumoursbusinessHuman
researchProduct

A pharmacological approach to gastric acid inhibition.

2005

Proton pump inhibitors have changed our approach to gastric acid-related diseases. They are much more potent acid inhibitors than H2-antagonists and exhibit a sophisticated mechanism of action. The present review analyses the general pharmacology of proton pump inhibitors and differentiates the specific characteristics of the various compounds that belong to this family. Special emphasis has been placed in describing the clinical implications of such differences and the potential importance for adverse effects.

Peptic UlcerChemistrymedicine.drug_classPharmacology toxicologyProton-pump inhibitorProton Pump InhibitorsAnti-Ulcer AgentsGastric AcidBiochemistryMechanism of actionmedicineGastric acidHumansPharmacology (medical)medicine.symptomAdverse effectDrugs
researchProduct

Cost-Effectiveness Analysis: Stress Ulcer Bleeding Prophylaxis with Proton Pump Inhibitors, H2 Receptor Antagonists

2012

Abstract Objectives Proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) present varying pharmacological efficacy in preventing stress ulcer bleeding (SUB) in intensive care units. The literature also reports disparate rates of ventilator-assisted pneumonia (VAP) as side effects of these treatments. We compared the cost-effectiveness of these two prophylactic pharmacological options. Methods We constructed a decision tree with a 60-day time horizon for patients at high risk for developing SUB, receiving either PPIs or H2RAs. For each treatment strategy, patients could be in one of three states of health: SUB, VAP, or no complication. Contemporary, clinically relevant probabilit…

Peptic Ulcermedicine.medical_specialtyMultivariate analysisDatabases FactualCost effectivenessmedicine.drug_classCost-Benefit AnalysisMEDLINEProton-pump inhibitorH2RAIntensive careInternal medicinemedicineHumanscost-effectivenessbusiness.industryHealth PolicyStress ulcerDecision TreesPublic Health Environmental and Occupational HealthProton Pump InhibitorsHealth Care CostsCost-effectiveness analysisLength of StayAnti-Ulcer Agentsmedicine.diseaseUnited StatesSurgerystress ulcer bleedingHistamine H2 AntagonistsMultivariate AnalysisGastrointestinal HemorrhagebusinessComplicationValue in Health
researchProduct

Trends in gastrointestinal bleeding in the Region of Valencia (2000-2005). Relationship to sales of nonsteroidal anti-inflammatory drugs and acid sup…

2011

Objective: To describe 2000-2005 time trends of prescription for NSAIDs, proton pump inhibitors (PPIs) and hospital admissions for gastrointestinal (GI) bleeding. Methods: Time series analysis of gastrointestinal (GI) bleeding admission and drugs’ Defined Daily Dose per 1000 people per day (DDD/1000/day) in the Region of Valencia, Spain, from January 2000 to December 2005. Results: Dispensation of NSAIDs went from 42.7 DDD/1000 people/day in 2000 to 58.3 DDD/1000 people/day in 2005. During the same period, dispensation of PPIs went from 26.3 DDD/1000 people/day to 68.5 DDD/1000 people/day (both are statistically significant). The rate of hospitalisations for gastrointestinal bleeding during…

Pharmacologymedicine.medical_specialtyGastrointestinal bleedingNonsteroidalTime FactorsGI bleedingTime trendsbusiness.industryAnti-Inflammatory Agents Non-SteroidalCommerceProton Pump Inhibitorsmedicine.diseaseSurgerychemistry.chemical_compoundDefined daily doseAcid suppressionchemistrySpainInternal medicinemedicineHumansMedical prescriptionbusinessGastrointestinal HemorrhageFarmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
researchProduct

Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis

2012

Background Routine second-look endoscopy in modern-era peptic ulcer bleeding (PUB) remains controversial. Objective To assess the effectiveness of routine second-look endoscopy in patients with PUB exhibiting high-risk stigmata after standard medical care and endoscopic therapy. Design Comprehensive literature searches (1990-2011) were performed, seeking randomized trials comparing a routine with an as-needed second endoscopy. Main Outcome Measurements The main outcome was rebleeding. Secondary outcomes were surgery and mortality. Subanalyses assessed the influence of study quality, rebleeding definitions, endoscopic hemostasis modality, and proton pump inhibitor (PPI) therapies. Analyses w…

Riskmedicine.medical_specialtymedicine.drug_classMEDLINEProton-pump inhibitorlaw.inventionRandomized controlled trialRecurrencelawOdds RatiomedicineHumansRadiology Nuclear Medicine and imagingModels Statisticalmedicine.diagnostic_testbusiness.industryHemostasis EndoscopicGastroenterologyProton Pump InhibitorsOdds ratioConfidence intervalSurgeryEndoscopyPeptic Ulcer HemorrhageTreatment OutcomeMeta-analysisHemostasisbusinessGastrointestinal Endoscopy
researchProduct

Light-driven proton transport of bacteriorhodopsin incorporated into long-term stable liposomes of a polymerizable sulfolipid

1983

Abstract The chromoprotein bacteriorhodopsin from Halobacterium halobium has been incorporated into liposomes made of a fully synthetic, polymerizable lipid. Bacteriorhodopsin is found to be active in these polymer liposomes. The advantage in the use of such polymer systems concerning long-term stability in comparison with liposomes made of natural lipid is demonstrated.

SulfolipidBiophysicsBacteriorhodopsinHalobacterium halobiumBiochemistrychemistry.chemical_compoundStructural BiologyChromoproteinProton transportGeneticsOrganic chemistryLight-driven proton pumpLong-term stabilityMolecular Biologychemistry.chemical_classificationLiposomebiologyBacteriorhodopsinCell BiologyPolymerLiposomechemistrybiological sciencesbiology.proteinLight drivenBiophysicsPolymerizable synthetic lipidFEBS Letters
researchProduct

Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination T…

2022

Background Drug-drug interactions are a major concern in oncology and may potentially affect the outcome of patients with cancer. Objective In this study, we aimed to determine whether the concomitant use of statins, metformin, or proton pump inhibitors affects survival in patients with metastatic renal cell carcinoma treated with first-line combination therapies. Methods Medical records of patients with documented metastatic renal cell carcinoma between January 2016 and November 2021 were reviewed at 17 participating centers. This research was conducted in ten institutions, including both referral centers and local hospitals. Patients were assessed for overall survival, progression-free su…

Vascular Endothelial Growth Factor ACancer ResearchAngiogenesis InhibitorsProton Pump InhibitorsKidney NeoplasmsMetforminTreatment OutcomeOncologyHumansPharmacology (medical)Hydroxymethylglutaryl-CoA Reductase InhibitorsCarcinoma Renal CellProtein Kinase InhibitorsRetrospective StudiesTargeted oncology
researchProduct